title: Should the 'echo guidelines' be followed in cancer patients?
authors.affiliation: Division of Cardiovascular Disease, Mayo Clinic & College of Medicine, 200 First Street SW, Rochester, MN 55905, USA.
authors.forename: Joerg
authors.initials: J
authors.lastname: Herrmann
authors.affiliation: Division of Cardiology, Department of Medicine, University of California at Los Angeles, Los Angeles, CA, USA.
authors.forename: Eric H
authors.initials: EH
authors.lastname: Yang
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects; D066126:Cardiotoxicity / Q000175:diagnosis; D002318:Cardiovascular Diseases / Q000175:diagnosis* / Q000209:etiology; D004452:Echocardiography; D005500:Follow-Up Studies; D017408:Guidelines as Topic; D006333:Heart Failure / Q000517:prevention & control; D006801:Humans; D009369:Neoplasms / Q000150:complications* / Q000503:physiopathology; D017741:Survivors; D019209:Troponin C / Q000097:blood; D018487:Ventricular Dysfunction, Left / Q000175:diagnosis
chemical_list: D000970:Antineoplastic Agents; D019209:Troponin C
keywords: cardiotoxicity; echocardiography; surveillance